Skip to main content
Premium Trial:

Request an Annual Quote

Caliper, Ambion to Co-Develop Microfluidics-Based RNA-Amplification Tool

NEW YORK, Oct. 28 - Caliper Technologies, Ambion, and an unnamed third party will use a $1.6 million NIH grant to develop an automated microfluidics-based RNA-amplification technology, the firms said today.

 

According to the companies, the proposed system will include a Caliper microfluidic LabChip product and a reagent kit made by Ambion to amplify reactions on the LabChip.

 

Caliper scientists will develop the chip while Ambion will develop the assay and tweak reagents. It was not immediately clear how long the R&D will take. Both companies together with the third party will pitch in to build the instrument.

 

The companies said they hope the new technology will increase throughput, decrease sample requirements, and boost consistency associated with RNA amplification.

 

The firms will use a $1.6 SBIR grant awarded to privately held Ambion by the NIH's National Institute of General Medical Sciences.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.